New combo therapy shows promise for Hard-to-Treat stomach cancer
NCT ID NCT01991379
First seen Dec 16, 2025 · Last updated May 22, 2026 · Updated 31 times
Summary
This study tests a combination of two drugs, MEK162 and imatinib, for people with advanced gastrointestinal stromal tumor (GIST). The goal is to find the best dose and see if the combination works better than imatinib alone. The study includes 75 participants who either have not been treated before or whose cancer has stopped responding to imatinib.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMOR (GIST) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.